Cysteamine Bitartrate Patent Expiration
Cysteamine Bitartrate is Used for treating nephropathic cystinosis. It was first introduced by Mylan Pharmaceuticals Inc
Cysteamine Bitartrate Patents
Given below is the list of patents protecting Cysteamine Bitartrate, along with the drug name that holds that patent and the company name owning that drug.
Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
---|---|---|---|---|
Procysbi | US10143665 | Methods for storing cysteamine formulations and related methods of treatment | Aug 16, 2036 | Horizon |
Procysbi |
US10143665 (Pediatric) | Methods for storing cysteamine formulations and related methods of treatment | Feb 16, 2037 | Horizon |
Procysbi | US10328037 | Methods for storing cysteamine formulations and related methods of treatment | Aug 16, 2036 | Horizon |
Procysbi |
US10328037 (Pediatric) | Methods for storing cysteamine formulations and related methods of treatment | Feb 16, 2037 | Horizon |
Procysbi | US10548859 | Methods for storing Cysteamine formulations and related methods of treatment | Aug 16, 2036 | Horizon |
Procysbi |
US10548859 (Pediatric) | Methods for storing Cysteamine formulations and related methods of treatment | Feb 16, 2037 | Horizon |
Procysbi | US10905662 | Methods for storing cysteamine formulations and related methods of treatment | Aug 16, 2036 | Horizon |
Procysbi |
US10905662 (Pediatric) | Methods for storing cysteamine formulations and related methods of treatment | Feb 16, 2037 | Horizon |
Procysbi | US8026284 | Enterically coated cystamine, cysteamine and derivatives thereof | Sep 22, 2027 | Horizon |
Procysbi |
US8026284 (Pediatric) | Enterically coated cystamine, cysteamine and derivatives thereof | Mar 22, 2028 | Horizon |
Procysbi | US8129433 | Enterically coated cysteamine, cystamine and derivatives thereof | Jan 26, 2027 | Horizon |
Procysbi | US9173851 | Delayed release cysteamine bead formulation, and methods of making and using same | Jun 17, 2034 | Horizon |
Procysbi |
US9173851 (Pediatric) | Delayed release cysteamine bead formulation, and methods of making and using same | Dec 17, 2034 | Horizon |
Procysbi | US9192590 | Enterically coated cysteamine, cystamine and derivatives thereof | Jan 26, 2027 | Horizon |
Procysbi |
US9192590 (Pediatric) | Enterically coated cysteamine, cystamine and derivatives thereof | Jul 26, 2027 | Horizon |
Procysbi | US9198882 | Enterically coated cysteamine, cystamine and derivatives thereof | Jan 26, 2027 | Horizon |
Procysbi |
US9198882 (Pediatric) | Enterically coated cysteamine, cystamine and derivatives thereof | Jul 26, 2027 | Horizon |
Procysbi | US9233077 | Delayed release cysteamine bead formulation, and methods of making and using same | Jun 17, 2034 | Horizon |
Procysbi |
US9233077 (Pediatric) | Delayed release cysteamine bead formulation, and methods of making and using same | Dec 17, 2034 | Horizon |
Procysbi | US9925156 | Enterically coated cysteamine, cystamine and derivatives thereof | Jan 26, 2027 | Horizon |
Procysbi | US9925156 | Enterically coated cysteamine, cystamine and derivatives thereof | Jan 26, 2027 | Horizon |
Procysbi |
US9925156 (Pediatric) | Enterically coated cysteamine, cystamine and derivatives thereof | Jul 26, 2027 | Horizon |
Procysbi | US9925157 | Enterically coated cysteamine, cystamine and derivatives thereof | Jan 26, 2027 | Horizon |
Procysbi | US9925157 | Enterically coated cysteamine, cystamine and derivatives thereof | Jan 26, 2027 | Horizon |
Procysbi |
US9925157 (Pediatric) | Enterically coated cysteamine, cystamine and derivatives thereof | Jul 26, 2027 | Horizon |
Procysbi | US9925158 | Enterically coated cysteamine, cystamine and derivatives thereof | Jan 26, 2027 | Horizon |
Procysbi | US9925158 | Enterically coated cysteamine, cystamine and derivatives thereof | Jan 26, 2027 | Horizon |
Procysbi |
US9925158 (Pediatric) | Enterically coated cysteamine, cystamine and derivatives thereof | Jul 26, 2027 | Horizon |
Coming Soon
Patent Strength Analyzer
![](/_nuxt/img/PatentAnalyzerAd.722976d.jpg)
YesNo
Thank you for your response 🥳